Cargando…

Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries

INTRODUCTION: Infections caused by carbapenem-resistant Enterobacteriaceae are a public health problem associated with higher mortality rates, longer hospitalization and increased healthcare costs. We carried out a study to describe the characteristics of patients with carbapenemase-producing Entero...

Descripción completa

Detalles Bibliográficos
Autores principales: Villegas, Maria Virginia, Pallares, Christian J., Escandón-Vargas, Kevin, Hernández-Gómez, Cristhian, Correa, Adriana, Álvarez, Carlos, Rosso, Fernando, Matta, Lorena, Luna, Carlos, Zurita, Jeannete, Mejía-Villatoro, Carlos, Rodríguez-Noriega, Eduardo, Seas, Carlos, Cortesía, Manuel, Guzmán-Suárez, Alfonso, Guzmán-Blanco, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841576/
https://www.ncbi.nlm.nih.gov/pubmed/27104910
http://dx.doi.org/10.1371/journal.pone.0154092
_version_ 1782428413438459904
author Villegas, Maria Virginia
Pallares, Christian J.
Escandón-Vargas, Kevin
Hernández-Gómez, Cristhian
Correa, Adriana
Álvarez, Carlos
Rosso, Fernando
Matta, Lorena
Luna, Carlos
Zurita, Jeannete
Mejía-Villatoro, Carlos
Rodríguez-Noriega, Eduardo
Seas, Carlos
Cortesía, Manuel
Guzmán-Suárez, Alfonso
Guzmán-Blanco, Manuel
author_facet Villegas, Maria Virginia
Pallares, Christian J.
Escandón-Vargas, Kevin
Hernández-Gómez, Cristhian
Correa, Adriana
Álvarez, Carlos
Rosso, Fernando
Matta, Lorena
Luna, Carlos
Zurita, Jeannete
Mejía-Villatoro, Carlos
Rodríguez-Noriega, Eduardo
Seas, Carlos
Cortesía, Manuel
Guzmán-Suárez, Alfonso
Guzmán-Blanco, Manuel
author_sort Villegas, Maria Virginia
collection PubMed
description INTRODUCTION: Infections caused by carbapenem-resistant Enterobacteriaceae are a public health problem associated with higher mortality rates, longer hospitalization and increased healthcare costs. We carried out a study to describe the characteristics of patients with carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE bloodstream infection (BSI) from Latin American hospitals and to determine the clinical impact in terms of mortality and antibiotic therapy. METHODS: Between July 2013 and November 2014, we conducted a multicenter observational study in 11 hospitals from 7 Latin American countries (Argentina, Colombia, Ecuador, Guatemala, Mexico, Peru, Venezuela). Patients with BSI caused by Enterobacteriaceae were included and classified either as CPE or non-CPE based on detection of bla(KPC), bla(VIM), bla(IMP), bla(NDM) and bla(OXA-48) by polymerase chain reaction. Enrolled subjects were followed until discharge or death. Demographic, microbiological and clinical characteristics were collected from medical records. Both descriptive and inferential statistics were used to analyze the information. RESULTS: A total of 255 patients with Enterobacteriaceae BSI were included; CPE were identified in 53 of them. In vitro non-susceptibility to all screened antibiotics was higher in the patients with CPE BSI, remaining colistin, tigecycline and amikacin as the most active drugs. Combination therapy was significantly more frequent in the CPE BSI group (p < 0.001). The most common regimen was carbapenem + colistin or polymyxin B. The overall mortality was 37% (94/255). Overall and attributable mortality were significantly higher in patients with CPE BSI (p < 0.001); however, we found that patients with CPE BSI who received combination therapy and those who received monotherapy had similar mortality. After multivariate adjustment, CPE BSI (adjusted odds ratio [aOR] 4; 95% confidence interval [CI] 1.7–9.5; p = 0.002) and critical illness (aOR 6.5; 95% CI 3.1–13.7; p < 0.001) were independently associated with in-hospital mortality. CONCLUSIONS: This study provides valuable data on the clinical characteristics and mortality risk factors in patients with CPE BSI. We determined that CPE infection is an independent mortality predictor and thus Latin American hospitals should perform campaigns on prevention and control of CPE BSI.
format Online
Article
Text
id pubmed-4841576
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48415762016-04-29 Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries Villegas, Maria Virginia Pallares, Christian J. Escandón-Vargas, Kevin Hernández-Gómez, Cristhian Correa, Adriana Álvarez, Carlos Rosso, Fernando Matta, Lorena Luna, Carlos Zurita, Jeannete Mejía-Villatoro, Carlos Rodríguez-Noriega, Eduardo Seas, Carlos Cortesía, Manuel Guzmán-Suárez, Alfonso Guzmán-Blanco, Manuel PLoS One Research Article INTRODUCTION: Infections caused by carbapenem-resistant Enterobacteriaceae are a public health problem associated with higher mortality rates, longer hospitalization and increased healthcare costs. We carried out a study to describe the characteristics of patients with carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE bloodstream infection (BSI) from Latin American hospitals and to determine the clinical impact in terms of mortality and antibiotic therapy. METHODS: Between July 2013 and November 2014, we conducted a multicenter observational study in 11 hospitals from 7 Latin American countries (Argentina, Colombia, Ecuador, Guatemala, Mexico, Peru, Venezuela). Patients with BSI caused by Enterobacteriaceae were included and classified either as CPE or non-CPE based on detection of bla(KPC), bla(VIM), bla(IMP), bla(NDM) and bla(OXA-48) by polymerase chain reaction. Enrolled subjects were followed until discharge or death. Demographic, microbiological and clinical characteristics were collected from medical records. Both descriptive and inferential statistics were used to analyze the information. RESULTS: A total of 255 patients with Enterobacteriaceae BSI were included; CPE were identified in 53 of them. In vitro non-susceptibility to all screened antibiotics was higher in the patients with CPE BSI, remaining colistin, tigecycline and amikacin as the most active drugs. Combination therapy was significantly more frequent in the CPE BSI group (p < 0.001). The most common regimen was carbapenem + colistin or polymyxin B. The overall mortality was 37% (94/255). Overall and attributable mortality were significantly higher in patients with CPE BSI (p < 0.001); however, we found that patients with CPE BSI who received combination therapy and those who received monotherapy had similar mortality. After multivariate adjustment, CPE BSI (adjusted odds ratio [aOR] 4; 95% confidence interval [CI] 1.7–9.5; p = 0.002) and critical illness (aOR 6.5; 95% CI 3.1–13.7; p < 0.001) were independently associated with in-hospital mortality. CONCLUSIONS: This study provides valuable data on the clinical characteristics and mortality risk factors in patients with CPE BSI. We determined that CPE infection is an independent mortality predictor and thus Latin American hospitals should perform campaigns on prevention and control of CPE BSI. Public Library of Science 2016-04-22 /pmc/articles/PMC4841576/ /pubmed/27104910 http://dx.doi.org/10.1371/journal.pone.0154092 Text en © 2016 Villegas et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Villegas, Maria Virginia
Pallares, Christian J.
Escandón-Vargas, Kevin
Hernández-Gómez, Cristhian
Correa, Adriana
Álvarez, Carlos
Rosso, Fernando
Matta, Lorena
Luna, Carlos
Zurita, Jeannete
Mejía-Villatoro, Carlos
Rodríguez-Noriega, Eduardo
Seas, Carlos
Cortesía, Manuel
Guzmán-Suárez, Alfonso
Guzmán-Blanco, Manuel
Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title_full Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title_fullStr Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title_full_unstemmed Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title_short Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries
title_sort characterization and clinical impact of bloodstream infection caused by carbapenemase-producing enterobacteriaceae in seven latin american countries
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841576/
https://www.ncbi.nlm.nih.gov/pubmed/27104910
http://dx.doi.org/10.1371/journal.pone.0154092
work_keys_str_mv AT villegasmariavirginia characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT pallareschristianj characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT escandonvargaskevin characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT hernandezgomezcristhian characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT correaadriana characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT alvarezcarlos characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT rossofernando characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT mattalorena characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT lunacarlos characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT zuritajeannete characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT mejiavillatorocarlos characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT rodrigueznoriegaeduardo characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT seascarlos characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT cortesiamanuel characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT guzmansuarezalfonso characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries
AT guzmanblancomanuel characterizationandclinicalimpactofbloodstreaminfectioncausedbycarbapenemaseproducingenterobacteriaceaeinsevenlatinamericancountries